EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study

Vergleichende Sicherheit und Wirksamkeit von Apixaban und Rivaroxaban zur Behandlung von krebsassoziierter venöser Thromboembolie: retrospektive Kohortenstudie

Jingjing Sun iD, Hemalkumar B Mehta iD, Jodi B Segal iD, G Caleb Alexander iD

PLOS Medicine · 26.09.2025 · 22 (9) · e1004754

DOI: 10.1371/journal.pmed.1004754 ↗

Auf einen Blick

Bei 6.329 Apixaban- und 4.260 Rivaroxaban-Anwender:innen war das Risiko für rezidivierende VTE und schwere Blutungen ähnlich; klinisch relevante nicht schwere Blutungen traten unter Apixaban seltener auf.

Fragestellung

Wie unterscheiden sich Sicherheit und Wirksamkeit von Apixaban und Rivaroxaban bei krebsassoziierter VTE?

Methode

Retrospektive Kohortenstudie mit Daten aus Medicare fee-for-service (2016–2020) und MarketScan (2016–2022); Gewichtung nach inverser Behandlungswahrscheinlichkeit und Cox-Modelle.

Ergebnisse

Nach 6 Monaten war Apixaban mit ähnlichem Risiko für rezidivierende VTE (HR 0,66; 95 %-KI 0,40–1,11) und schwere Blutungen (HR 0,95; 95 %-KI 0,73–1,23) verbunden, aber mit geringerem Risiko für klinisch relevante nicht schwere Blutungen (HR 0,84; 95 %-KI 0,74–0,96).

Einschränkungen

Beobachtungsdesign; trotz Anpassung durch inverse probability weighting könnten Residualkonfundierungen bestehen.

Schlussfolgerung der Autor:innen

Bei krebsassoziierter VTE war Apixaban mit ähnlichem Risiko für rezidivierende VTE und schwere Blutungen sowie geringerem Risiko für klinisch relevante nicht schwere Blutungen assoziiert.

Kernaussagen

  • Rezidivierende VTE: HR 0,66; 95 %-KI 0,40–1,11
  • Schwere Blutung: HR 0,95; 95 %-KI 0,73–1,23
  • Klinisch relevante nicht schwere Blutung: HR 0,84; 95 %-KI 0,74–0,96

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS Medicine, online erschienen am 26.09.2025. Verfasst von Jingjing Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Pyrazoles, Pyridones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While apixaban has demonstrated advantages over alternative direct oral anticoagulants (DOACs) in some settings, its comparative safety and effectiveness in cancer-associated venous thromboembolism (VTE) remain uncertain. Current guidelines recommend DOACs as first-line treatment for cancer-associated VTE, though they do not recommend any specific DOAC over another. This study aimed to quantify the risk of recurrent VTE, major bleeding, and clinically relevant non-major bleeding among individuals with cancer-associated VTE treated with apixaban versus rivaroxaban. Methods and findings In this retrospective cohort study, we used data from Medicare fee-for-service (2016–2020) and MarketScan (2016–2022), two U.S. administrative claims databases covering publicly and commercially insured individuals. We included individuals aged ≥65 years (Medicare) or 18–64 years (MarketScan) with active cancer, defined as a cancer diagnosis within 6 months before an index VTE event, who newly initiated apixaban or rivaroxaban within 30 days of that event. The outcomes were (1) hospitalization for recurrent VTE; (2) hospitalization for major bleeding; and (3) hospitalization or outpatient visit for clinically relevant non-major bleeding events. Eligible individuals were followed for outcomes at 6 months (consistent with guideline recommendations) and during the entire follow-up period. We used inverse probability of treatment weighting to adjust for baseline differences, including demographics, comorbidities (e.g., prior bleed), VTE risk factors, cancer type and treatments, and medication use, and applied inverse probability of censoring weighting to account for differential loss to follow-up. We analyzed outcomes using adjusted Cox proportional hazards models, pooling estimates using an inverse variance-weighted fixed-effects model. The final cohort included 6,329 apixaban and 4,260 rivaroxaban users across both databases. At 6 months, apixaban was associated with similar risks of recurrent VTE (hazard ratio [HR] 0.66, 95% confidence interval [CI] [0.40, 1.11]; p -value = 0.11) and major bleeding (HR 0.95, 95% CI [0.73, 1.23]; p = 0.70), and a lower risk of clinically relevant non-major bleeding (HR 0.84, 95% CI [0.74, 0.96]; p = 0.009) compared to rivaroxaban. The same pattern persisted during the extended follow‑up. The main limitation is the observational design, which may leave residual confounding despite adjustments using inverse probability weighting.

Conclusions

In cancer-associated VTE, apixaban was associated with similar risks of recurrent VTE and major bleeding, and a lower risk of clinically relevant non-major bleeding compared with rivaroxaban. These findings suggest apixaban may be a favorable option for anticoagulation in cancer-associated VTE when minimizing bleeding risk is a priority.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThromboembolismPyrazolesPyridonesNeoplasmsFactor Xa InhibitorsHumansRetrospective StudiesMaleFemaleAgedMiddle AgedHemorrhageAdultYoung AdultAdolescentTreatment OutcomeUnited StatesAnticoagulantsRecurrence

Substanzen

apixabanRivaroxabanPyrazolesPyridonesFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, United States of America.

ORCID-Profile: Jingjing Sun, Hemalkumar B Mehta, Jodi B Segal, G Caleb Alexander

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging

Zitieren

APA

Sun, J., Mehta, H. B., Segal, J. B., & Alexander, G. C. (2025). Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study. PLOS Medicine, 22(9), e1004754. https://doi.org/10.1371/journal.pmed.1004754

Vancouver

Sun J, Mehta HB, Segal JB, Alexander GC. Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study. PLOS Medicine. 2025;22(9):e1004754. doi:10.1371/journal.pmed.1004754

BibTeX
@article{Sun2025,
  author = {Sun, Jingjing and Mehta, Hemalkumar B and Segal, Jodi B and Alexander, G Caleb},
  title = {Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study},
  journal = {PLOS Medicine},
  year = {2025},
  volume = {22},
  number = {9},
  pages = {e1004754},
  doi = {10.1371/journal.pmed.1004754}
}
Kostenlos starten →